Sverige - svenska - Läkemedelsverket (Medical Products Agency)

abcur ab - metadonhydroklorid - tablett - 20 mg - laktosmonohydrat hjälpämne; metadonhydroklorid 20 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

abcur ab - metadonhydroklorid - tablett - 40 mg - metadonhydroklorid 40 mg aktiv substans; laktosmonohydrat hjälpämne

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

ebb medical ab - trimetoprim - tablett - 100 mg - laktosmonohydrat hjälpämne; propylenglykol hjälpämne; trimetoprim 100 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

ebb medical ab - trimetoprim - tablett - 160 mg - trimetoprim 160 mg aktiv substans; propylenglykol hjälpämne; laktosmonohydrat hjälpämne

Europeiska unionen - svenska - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - graftförkastning - immunsuppressiva - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

krka sverige ab - atorvastatinkalcium, amorft - filmdragerad tablett - 10 mg - laktosmonohydrat hjälpämne; atorvastatinkalcium, amorft 10,36 mg aktiv substans; natriumlaurilsulfat hjälpämne - atorvastatin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

actavis group ptc ehf. - atorvastatinkalciumtrihydrat - filmdragerad tablett - 10 mg - atorvastatinkalciumtrihydrat 10,84 mg aktiv substans; mannitol hjälpämne - atorvastatin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

krka sverige ab - atorvastatinkalcium, amorft - filmdragerad tablett - 20 mg - laktosmonohydrat hjälpämne; atorvastatinkalcium, amorft 20,72 mg aktiv substans; natriumlaurilsulfat hjälpämne - atorvastatin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

actavis group ptc ehf. - atorvastatinkalciumtrihydrat - filmdragerad tablett - 20 mg - mannitol hjälpämne; atorvastatinkalciumtrihydrat 21,69 mg aktiv substans - atorvastatin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

krka sverige ab - atorvastatinkalcium, amorft - filmdragerad tablett - 40 mg - atorvastatinkalcium, amorft 41,44 mg aktiv substans; natriumlaurilsulfat hjälpämne; laktosmonohydrat hjälpämne - atorvastatin